|
1
|
Dinesen LC, Walsh AJ, Protic MN, Heap G,
Cummings F, Warren BF, George B, Mortensen NJ and Travis SP: The
pattern and outcome of acute severe colitis. J Crohn's Colitis.
4:431–437. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Edwards FC and Truelove SC: The course and
prognosis of ulcerative colitis. Gut. 4:299–315. 1963.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Macken L and Blaker PA: Management of
acute severe ulcerative colitis (NICE CG 166). Clin Med (Lond).
15:473–476. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Park KT, Tsai R, Perez F, Cipriano LE,
Bass D and Garber AM: Cost-effectiveness of early colectomy with
ileal pouch-anal anastamosis versus standard medical therapy in
severe ulcerative colitis. Ann Surg. 256:117–124. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Han W, Xu JM, Hu NZ, Mei Q and Liu MW:
Early predictors of responses and clinical outcomes of
corticosteroid treatment for severe ulcerative colitis. Scand J
Gastroenterol. 49:424–433. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Travis S, Satsangi J and Lémann M:
Predicting the need for colectomy in severe ulcerative colitis: A
critical appraisal of clinical parameters and currently available
biomarkers. Gut. 60:3–9. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Walsh AJ, Ghosh A, Brain AO, Buchel O,
Burger D, Thomas S, White L, Collins GS, Keshav S and Travis SP:
Comparing disease activity indices in ulcerative colitis. J Crohn's
Colitis. 8:318–325. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
D'Haens G, Sandborn WJ, Feagan BG, Geboes
K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P,
Schölmerich J, et al: A review of activity indices and efficacy end
points for clinical trials of medical therapy in adults with
ulcerative colitis. Gastroenterology. 132:763–786. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Travis SPL, Schnell D, Krzeski P, Abreu
MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M,
Lichtenstein GR, et al: Developing an instrument to assess the
endoscopic severity of ulcerative colitis: The Ulcerative Colitis
Endoscopic Index of Severity (UCEIS). Gut. 61:535–542.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Travis S, Corte C and Keshav S: Does
disease extent matter when scoring the UCEIS? J Crohn's Colitis.
9(694)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Travis SPL, Schnell D, Feagan BG, Abreu
MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR,
Mary JY, et al: The impact of clinical information on the
assessment of endoscopic activity: Characteristics of the
ulcerative colitis endoscopic index of severity. J Crohn's Colitis.
9:607–616. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fefferman DS and Farrell RJ: Endoscopy in
inflammatory bowel disease: Indications, surveillance, and use in
clinical practice. Clin Gastroenterol Hepatol. 3:11–24.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Røseth AG, Aadland E, Jahnsen J and
Raknerud N: Assessment of disease activity in ulcerative colitis by
faecal calprotectin, a novel granulocyte marker protein. Digestion.
58:176–180. 1997.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lobatón T, Rodríguez-Moranta F, Lopez A,
Sánchez E, Rodríguez-Alonso L and Guardiola J: A new rapid
quantitative test for fecal calprotectin predicts endoscopic
activity in ulcerative colitis. Inflamm Bowel Dis. 19:1034–1042.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fagerhol MK: Calprotectin, a faecal marker
of organic gastrointestinal abnormality. Lancet. 356:1783–1784.
2000.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Goenka MK, Nag S, Kumar A and Pai CG:
Diagnosis of acute severe colitis. Trop Gastroenterol. 35 (Suppl
1):S1–S8. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Chinese Medical Association Digestive
Diseases Branch Inflammatory Bowel Disease Cooperative Group.
Consensus on the diagnosis and treatment of inflammatory bowel
disease in China. Chin J Integr Med. 47:73–79. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F,
Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, et al:
Mortality associated with medical therapy versus elective colectomy
in ulcerative colitis: A cohort study. Ann Intern Med. 163:262–270.
2015.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Andersson P, Söderholm JD and Derholm JD:
Surgery in ulcerative colitis: Indication and timing. Dig Dis.
27:335–340. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gulliford SR and Limdi JK: Acute severe
ulcerative colitis: Timing is everything. Postgrad Med J.
87:215–222. 2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Travis SP, Farrant JM, Ricketts C, Nolan
DJ, Mortensen NM, Kettlewell MG and Jewell DP: Predicting outcome
in severe ulcerative colitis. Gut. 38:905–910. 1996.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lindgren SC, Flood LM, Kilander AF,
Löfberg R, Persson TB and Sjödahl RI: Early predictors of
glucocorticosteroid treatment failure in severe and moderately
severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol.
10:831–835. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ho GT, Mowat C, Goddard CJ, Fennell JM,
Shah NB, Prescott RJ and Satsangi J: Predicting the outcome of
severe ulcerative colitis: Development of a novel risk score to aid
early selection of patients for second-line medical therapy or
surgery. Aliment Pharmacol Ther. 19:1079–1087. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Järnerot G, Hertervig E, Friis-Liby I,
Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A,
Verbaan H, et al: Infliximab as rescue therapy in severe to
moderately severe ulcerative colitis: A randomized,
placebo-controlled study. Gastroenterology. 128:1805–1811.
2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Baron JH, Connell AM and Lennard-Jones JE:
Variation between observers in describing mucosal appearances in
proctocolitis. BMJ. 1:89–92. 1964.PubMed/NCBI View Article : Google Scholar
|
